Niagen Bioscience to present at Longevity Investors Conference

0 min read | Published on 02 Sept 2026, 06:28 PM |Updated on 02 Sept 2026, 06:28 PM

Reviewed by

Shriram SScanX News Team

Add as a preferred
source on Google

Key Highlights

Niagen Bioscience management will attend the Longevity Investors Conference in Gstaad from September 14-17, 2026
CEO Rob Fried will speak on a consumer health panel on September 16 at 14:50 p.m. CEST
CFO Ozan Pamir will join for one-on-one investor meetings throughout the event
Attendees can sample Tru Niagen and Niagen Plus products on-site

*this image is generated using AI for illustrative purposes only.

Niagen Bioscience, Inc. (NASDAQ: NAGE) will participate in the Longevity Investors Conference in Gstaad, Switzerland, from September 14 to 17, 2026. Senior management aims to engage with institutional investors and scientists on the company’s NAD+ science strategy.

CEO Rob Fried will speak on the "Longevity Goes Mainstream: The Investment Case for Consumer Health" panel on Wednesday, September 16, from 14:50 to 15:30 p.m. CEST. He will be joined by Chief Financial Officer Ozan Pamir for one-on-one investor meetings throughout the event.

Conference Details

The conference features discussions on breakthrough research shaping the longevity sector. Attendees can sample Tru Niagen and experience Niagen Plus on-site. The event targets institutional investors, family offices, and funds.

Event Detail	Information
Conference	Longevity Investors Conference
Dates	September 14-17, 2026
Location	Gstaad, Switzerland
Panel Topic	Longevity Goes Mainstream

Investors seeking meetings should contact their conference representative or email Niagen@KCSA.com . Niagen Bioscience remains the global authority on NAD+ science, focusing on healthy aging through its patented nicotinamide riboside technology.

Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

How might the 'Longevity Goes Mainstream' narrative presented by CEO Rob Fried influence institutional capital allocation towards consumer health versus pure biotech R&D in the NAD+ sector?

What specific clinical or commercial milestones does Niagen Bioscience need to achieve post-conference to validate its claim as the global authority on NAD+ science against emerging competitors?

Could the direct sampling of Tru Niagen and Niagen Plus at the conference lead to measurable shifts in brand perception among family offices and funds, potentially impacting short-term stock volatility?

Niagen Bioscience CFO presents at Nasdaq X LD Micro SF summit

0 min read | Published on 26 Aug 2026, 06:36 PM |Updated on 26 Aug 2026, 06:36 PM

Reviewed by

Ashish TScanX News Team

Add as a preferred
source on Google

Key Highlights

Niagen Bioscience CFO Ozan Pamir presents at Nasdaq X LD Micro SF Summit on September 9, 2026
Event features 15-minute presentations and breakout sessions for 25 curated public companies
Pamir available for one-on-one meetings with institutional investors in San Francisco
Company highlights Tru Niagen as top US NAD+ supplement by revenue in 2025

*this image is generated using AI for illustrative purposes only.

Niagen Bioscience, Inc. (NASDAQ: NAGE) announced that its senior management will participate in the Nasdaq X LD Micro Inaugural SF Summit on September 9, 2026, in San Francisco. The event aims to connect curated public companies with institutional investors.

Conference Details

Nasdaq is partnering with LD Micro to host 25 public companies at the Nasdaq San Francisco office. Each company will deliver a 15-minute presentation followed by a dedicated 15-minute breakout session for investor engagement.

Niagen Bioscience CFO Ozan Pamir is scheduled to present at 11:20 am PT. He will also be available for one-on-one meetings with institutional investors during the conference.

Investor Engagement

Investors interested in scheduling a one-on-one meeting with the Niagen Bioscience management team can contact their respective conference representative or email Niagen@KCSA.com .

About Niagen Bioscience

Niagen Bioscience positions itself as the global authority on NAD+ (nicotinamide adenine dinucleotide) science and healthy aging. Its product portfolio includes Tru Niagen, described as the number one NAD+ boosting oral supplement in the United States based on revenue per the largest U.S. e-commerce marketplace from January 2025 to December 2025. The company also offers Niagen Plus, featuring pharmaceutical-grade intravenous and injectable products available exclusively at clinics with a prescription.

Disclaimer: This article is AI-generated using data from ViewTrade. ScanX is not liable for any inaccuracies.

How might the outcome of the Nasdaq X LD Micro Summit influence Niagen Bioscience's institutional investor base and stock liquidity in Q4 2026?

What specific growth metrics or clinical data regarding Tru Niagen and Niagen Plus is CFO Ozan Pamir likely to highlight to justify valuation multiples?

Could the exclusive prescription model for Niagen Plus face regulatory or reimbursement hurdles that might impact its projected revenue contribution?